Home Cart Sign in  
Chemical Structure| 1772-03-8 Chemical Structure| 1772-03-8

Structure of D-(+)-Galactosamine HCI
CAS No.: 1772-03-8

Chemical Structure| 1772-03-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

D-(+)-Galactosamine HCl is an experimental toxin that causes liver damage by generating free radicals and depleting UTP nucleotides, commonly used to induce acute liver injury in animal models.

Synonyms: D-Galactosamine hydrochloride; D-(+)-Galactosamine; D(+)-Galactosamine hydrochloride

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of D-(+)-Galactosamine HCI

CAS No. :1772-03-8
Formula : C6H14ClNO5
M.W : 215.63
SMILES Code : O=C[C@H](N)[C@@H](O)[C@@H](O)[C@H](O)CO.[H]Cl
Synonyms :
D-Galactosamine hydrochloride; D-(+)-Galactosamine; D(+)-Galactosamine hydrochloride
MDL No. :MFCD00135830

Safety of D-(+)-Galactosamine HCI

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P261-P280-P305+P351+P338

Isoform Comparison

Biological Activity

Description
D(+)-Galactosamine hydrochloride, a well-known experimental toxin, primarily inflicts liver damage through free radical production and UTP nucleotide depletion. Intoxication with D(+)-Galactosamine hydrochloride also leads to renal dysfunction, often culminating in renal failure associated with severe liver damage. The combination of Lipopolysaccharide and D(+)-Galactosamine-induced acute liver injury serves as an established animal model for fulminant hepatic failure[1].[2].

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice LPS/D-GalN-induced acute liver injury model Intraperitoneal injection 700 mg/kg Single injection, sacrificed after 5 hours To investigate the role of the Notch1-YAP pathway in acute liver injury. Results showed that Notch1-deficient mice exhibited reduced liver injury, decreased macrophage/neutrophil infiltration, lower pro-inflammatory cytokine expression, and increased anti-inflammatory cytokine expression. Cell Mol Gastroenterol Hepatol. 2023;15(5):1085-1104
Mice D-galactosamine-sensitized mouse model Intraperitoneal injection 18 mg/25 g Single dose, co-administered with endotoxin or TNF D-galactosamine sensitizes mice to the lethal effects of endotoxin and TNF/cachectin by depleting uridine nucleotides, leading to liver injury. J Exp Med. 1991 Feb 1;173(2):357-65
Wistar rats Acute liver injury model Intraperitoneal injection 400 mg/kg Single injection, observed for 6 hours to 72 hours D-GalN induced ALI via mitochondrial apoptosis- and proinflammatory cytokine-signaling pathways, leading to increased ROS production, hepatocyte apoptosis, and plasma multiple cytokines and chemokines. Green tea extract pretreatment attenuated these effects by enhancing anti-apoptotic mechanisms. J Biomed Sci. 2009 Mar 25;16(1):35
Mice GalN/LPS-induced acute liver failure model Intraperitoneal injection 500 mg/kg Single injection, observed for 24 hours 50-AMP pretreatment significantly increased survival rate, reduced serum AST and ALT levels, and attenuated liver necrosis and inflammatory cell infiltration Cell Death Dis. 2014 Jan 9;5(1):e985
ICR mice GalN/LPS-induced fulminant hepatic failure model Intraperitoneal injection 800 mg/kg Single injection, observed for 24 hours To investigate the protective effect of afzelin against GalN/LPS-induced fulminant hepatic failure. Results showed that afzelin improved survival rate, reduced serum ALT levels and pro-inflammatory cytokines, and ameliorated mitochondrial function. Br J Pharmacol. 2017 Jan;174(2):195-209
BALB/c mice LPS/d-GalN-induced fulminant hepatic failure model Intraperitoneal injection 600 mg/kg Twice at a 12-h interval, followed by LPS/d-GalN challenge To investigate the protective effect of AA against LPS/d-GalN-induced fulminant hepatic failure, it was found that AA pretreatment significantly increased survival rate, decreased ALT and AST levels, and alleviated liver pathological changes. Front Immunol. 2017 Jul 7;8:785
C57BL/6 mice Acute liver injury model induced by D-galactosamine/LPS (GalN/LPS) Intraperitoneal injection 800 μg/g Single injection, lasting 6 hours Evaluate the effect of OCA on hepatocyte apoptosis in an acute liver injury model. OCA pretreatment did not significantly affect serum transaminase levels and hepatocyte apoptosis. Acta Pharm Sin B. 2019 May;9(3):526-536

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.64mL

0.93mL

0.46mL

23.19mL

4.64mL

2.32mL

46.38mL

9.28mL

4.64mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories